A strategy for risk mitigation of antibodies with fast clearance

mAbs

Volumn 4, Issue 6, 2012, Pages 753-760

  Hötzel, Isidro ^a   Theil, Frank Peter ^a   Bernstein, Lisa J ^a   Prabhu, Saileta ^a   Deng, Rong ^a   Quintana, Leah ^a   Lutman, Jeff ^a   Sibia, Renuka ^a   Chan, Pamela ^a   Bumbaca, Daniela ^a   Fielder, Paul ^a   Carter, Paul J ^a   Kelley, Robert F ^a  

^a GENENTECH INC   (United States)

Author keywords

Antibody; Baculovirus; FcRn; Non specific binding; Pharmacokinetics

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1; MONOCLONAL ANTIBODY 10; MONOCLONAL ANTIBODY 11; MONOCLONAL ANTIBODY 12; MONOCLONAL ANTIBODY 13; MONOCLONAL ANTIBODY 14; MONOCLONAL ANTIBODY 15; MONOCLONAL ANTIBODY 16; MONOCLONAL ANTIBODY 17; MONOCLONAL ANTIBODY 18; MONOCLONAL ANTIBODY 19; MONOCLONAL ANTIBODY 2; MONOCLONAL ANTIBODY 20; MONOCLONAL ANTIBODY 21; MONOCLONAL ANTIBODY 22; MONOCLONAL ANTIBODY 24; MONOCLONAL ANTIBODY 3; MONOCLONAL ANTIBODY 33; MONOCLONAL ANTIBODY 4; MONOCLONAL ANTIBODY 44; MONOCLONAL ANTIBODY 47; MONOCLONAL ANTIBODY 47B; MONOCLONAL ANTIBODY 47C; MONOCLONAL ANTIBODY 5; MONOCLONAL ANTIBODY 6; MONOCLONAL ANTIBODY 7; MONOCLONAL ANTIBODY 8; MONOCLONAL ANTIBODY 9; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BACULOVIRUS; BINDING AFFINITY; DRUG CLEARANCE; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HAPLORHINI;

ANTIBODY; BACULOVIRUS; FCRN; NON-SPECIFIC BINDING; PHARMACOKINETICS;

ANIMALS; ANTIBODIES, MONOCLONAL; BACULOVIRIDAE; DRUG DISCOVERY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; PROTEIN BINDING; RISK ADJUSTMENT; VIRION;

EID: 84869840045     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22189     Document Type: Article

References (31)

1. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931
2. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548-58; PMID:18784655; http://dx.doi.org/10.1038/clpt.2008.170
3. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11:81-8; PMID:16478695; http://dx.doi.org/10.1016/S1359-6446(05)03638-X
4. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006; 72:1-10; PMID:16469301; http://dx.doi.org/10.1016/j.bcp.2005.12. 041
5. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 2010; 24:23-39; PMID:20055530; http://dx.doi.org/10.2165/11530560-000000000-00000
6. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs 2011; 3:422-30; PMID:22048693; http://dx.doi.org/10.4161/mabs.3.5.16983
7. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:493-507; PMID:20608753; http://dx.doi.org/10.2165/11531280-000000000-00000
8. Deng R, Iyer S, Theil F-P, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011; 3:61-6; PMID:20962582; http://dx.doi.org/10.4161/ mabs.3.1.13799
9. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-24; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
10. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176:346-56; PMID:16365427
11. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-71; PMID:19494290; http://dx.doi.org/10.4049/jimmunol.0804182
12. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157-9; PMID:20081867; http://dx.doi.org/10.1038/nbt.1601
13. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368:652-65; PMID:17362988; http://dx.doi.org/10.1016/j.jmb. 2007.02.024
14. Bumbaca D, Wong A, Drake E, Reyes AE 2nd, Lin BC, Stephan J-P, et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 2011; 3:376-86; PMID:21540647; http://dx.doi.org/10.4161/mabs.3.4.15786
15. Vugmeyster Y, Szklut P, Wensel D, Ross J, Xu X, Awwad M, et al. Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species. Pharm Res 2011; 28:1696-706; PMID:21424161; http://dx.doi.org/10.1007/s11095-011-0405-x
16. Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M, Widom A, et al. In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs 2010; 2:335-46; PMID:20424514; http://dx.doi.org/10.4161/mabs.2.3.11850
17. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30:105-8; PMID:8417368; http://dx.doi.org/10.1016/0161-5890(93)90432-B
18. Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 2004; 340:1073-93; PMID:15236968; http://dx.doi.org/10.1016/j.jmb.2004.05.051
19. Yeung YA, Wu X, Reyes AE 2nd, Vernes JM, Lien S, Lowe J, et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010; 70:3269-77; PMID:20354184; http://dx.doi.org/10.1158/0008-5472.CAN-09-4580
20. Dennis MS, Lowman HB. Phage selection strategies for improved affinity and specificity of proteins and peptides. In: Clackson T, Lowman HB, eds. Phage Display. Oxford, UK: Oxford University Press, 2004:61-94
21. Hötzel I, Chiang V, Diao J, Pantua H, Maun HR, Kapadia SB. Efficient production of antibodies against a mammalian integral membrane protein by phage display. Protein Eng Des Sel 2011; 24:679-89; PMID:21810920; http://dx.doi.org/10.1093/protein/gzr039
22. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, et al. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39:1469-77; PMID:21610128; http://dx.doi.org/10.1124/dmd.111.039453
23. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385-92; PMID:20159773; http://dx.doi.org/10.1093/ protein/gzq009
24. Winzor DJ. Determination of the net charge (valence) of a protein: a fundamental but elusive parameter. Anal Biochem 2004; 325:1-20; PMID:14715279; http://dx.doi.org/10.1016/j.ab.2003.09.035
25. Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm 2012; 9:791-802; PMID:22352470; http://dx.doi.org/10.1021/ mp200566k
26. Marheineke K. Lipid Composition of Spodoptera frugiperda (Sf9) and Trichplusia ni (Tn) insect cells used for baculovirus infection. FEBS Lett 1998; 441:4; http://dx.doi.org/10.1016/S0014-5793(98)01523-3
27. Wang R, Deng F, Hou D, Zhao Y, Guo L, Wang H, et al. Proteomics of the Autographa californica nucleopolyhedrovirus budded virions. J Virol 2010; 84:7233-42; PMID:20444894; http://dx.doi.org/10.1128/JVI.00040-10
28. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38:600-5; PMID:20071453; http://dx.doi.org/10.1124/dmd. 109.031310
29. Säfsten P, Klakamp SL, Drake AW, Karlsson R, Myszka DG. Screening antibody-antigen interactions in parallel using Biacore A100. Anal Biochem 2006; 353:181-90; PMID:16510107; http://dx.doi.org/10.1016/j.ab.2006.01.041
30. Stone M. Cross-validatory choice and assessment of statistical predictions. J R Stat Soc, B 1974; 36:111-47
31. Geisser S. The predictive sample reuse method with applications I. Amer Stat Assoc 1975; 70:320-8; http://dx.doi.org/10.1080/01621459.1975.10479865